Pseudomyxoma peritonei medical therapy: Difference between revisions
Nima Nasiri (talk | contribs) |
Nima Nasiri (talk | contribs) |
||
| Line 3: | Line 3: | ||
{{CMG}}{{AE}}{{PSD}} | {{CMG}}{{AE}}{{PSD}} | ||
==Overview== | ==Overview== | ||
Pseudomyxoma peritonei (PMP) is a rare condition consisting of intraperitoneal mucinous tumors and ascites, most commonly arises from mucinous tumors of the appendix., with a prevalence of approximately 1–2 persons per million per year. | Pseudomyxoma peritonei (PMP) is a rare condition consisting of intraperitoneal mucinous tumors and ascites, most commonly arises from mucinous tumors of the appendix., with a prevalence of approximately 1–2 persons per million per year. It is a slowly progressive disease process with a large amount of mucus containing occasional epithelial cells. PMP is histologically classified into disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA). | ||
==Medical Therapy== | ==Medical Therapy== | ||
Revision as of 18:08, 7 January 2019
|
Pseudomyxoma peritonei Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pseudomyxoma peritonei medical therapy On the Web |
|
American Roentgen Ray Society Images of Pseudomyxoma peritonei medical therapy |
|
Risk calculators and risk factors for Pseudomyxoma peritonei medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Pseudomyxoma peritonei (PMP) is a rare condition consisting of intraperitoneal mucinous tumors and ascites, most commonly arises from mucinous tumors of the appendix., with a prevalence of approximately 1–2 persons per million per year. It is a slowly progressive disease process with a large amount of mucus containing occasional epithelial cells. PMP is histologically classified into disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA).
Medical Therapy
Mainstay of treatment for pseudomyxoma peritonei is cytoreductive surgery combined with intraperitoneal chemotherapy with mitomycin at 42°C.[1][2]
References
- ↑ Chen, Chin-Fan; Huang, Che-Jen; Kang, Wan-Yi; Hsieh, Jan-Sing (2008). "Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin / fluorouracil /leucovorin (FOLFOX4)". World Journal of Surgical Oncology. 6 (1): 118. doi:10.1186/1477-7819-6-118. ISSN 1477-7819.
- ↑ Sugarbaker, Paul H (2006). "New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?". The Lancet Oncology. 7 (1): 69–76. doi:10.1016/S1470-2045(05)70539-8. ISSN 1470-2045.